Similar articles for PMID: 31217428

Year	Number of Results
1982	1
2006	2
2007	1
2008	1
2010	2
2011	3
2012	4
2013	7
2014	8
2015	14
2016	13
2017	19
2018	13
2019	11
2020	6
2021	2

1

Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia.

Minuesa G, Albanese SK, Xie W, Kazansky Y, Worroll D, Chow A, Schurer A, Park SM, Rotsides CZ, Taggart J, Rizzi A, Naden LN, Chou T, Gourkanti S, Cappel D, Passarelli MC, Fairchild L, Adura C, Glickman JF, Schulman J, Famulare C, Patel M, Eibl JK, Ross GM, Bhattacharya S, Tan DS, Leslie CS, Beuming T, Patel DJ, Goldgur Y, Chodera JD, Kharas MG. Minuesa G, et al. Nat Commun. 2019 Jun 19;10(1):2691. doi: 10.1038/s41467-019-10523-3. Nat Commun. 2019. PMID: 31217428 Free PMC article.

2

Musashi-2 Silencing Exerts Potent Activity against Acute Myeloid Leukemia and Enhances Chemosensitivity to Daunorubicin.

Han Y, Ye A, Zhang Y, Cai Z, Wang W, Sun L, Jiang S, Wu J, Yu K, Zhang S. Han Y, et al. PLoS One. 2015 Aug 26;10(8):e0136484. doi: 10.1371/journal.pone.0136484. eCollection 2015. PLoS One. 2015. PMID: 26308531 Free PMC article.

3

Transcriptome-wide analysis uncovers the targets of the RNA-binding protein MSI2 and effects of MSI2's RNA-binding activity on IL-6 signaling.

Duggimpudi S, Kloetgen A, Maney SK, Münch PC, Hezaveh K, Shaykhalishahi H, Hoyer W, McHardy AC, Lang PA, Borkhardt A, Hoell JI. Duggimpudi S, et al. J Biol Chem. 2018 Oct 5;293(40):15359-15369. doi: 10.1074/jbc.RA118.002243. Epub 2018 Aug 20. J Biol Chem. 2018. PMID: 30126842 Free PMC article.

4

Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia.

Kharas MG, Lengner CJ, Al-Shahrour F, Bullinger L, Ball B, Zaidi S, Morgan K, Tam W, Paktinat M, Okabe R, Gozo M, Einhorn W, Lane SW, Scholl C, Fröhling S, Fleming M, Ebert BL, Gilliland DG, Jaenisch R, Daley GQ. Kharas MG, et al. Nat Med. 2010 Aug;16(8):903-8. doi: 10.1038/nm.2187. Epub 2010 Jul 8. Nat Med. 2010. PMID: 20616797 Free PMC article.

5

The splicing factor RBM25 controls MYC activity in acute myeloid leukemia.

Ge Y, Schuster MB, Pundhir S, Rapin N, Bagger FO, Sidiropoulos N, Hashem N, Porse BT. Ge Y, et al. Nat Commun. 2019 Jan 11;10(1):172. doi: 10.1038/s41467-018-08076-y. Nat Commun. 2019. PMID: 30635567 Free PMC article.

6

Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells.

Vu LP, Prieto C, Amin EM, Chhangawala S, Krivtsov A, Calvo-Vidal MN, Chou T, Chow A, Minuesa G, Park SM, Barlowe TS, Taggart J, Tivnan P, Deering RP, Chu LP, Kwon JA, Meydan C, Perales-Paton J, Arshi A, Gönen M, Famulare C, Patel M, Paietta E, Tallman MS, Lu Y, Glass J, Garret-Bakelman FE, Melnick A, Levine R, Al-Shahrour F, Järås M, Hacohen N, Hwang A, Garippa R, Lengner CJ, Armstrong SA, Cerchietti L, Cowley GS, Root D, Doench J, Leslie C, Ebert BL, Kharas MG. Vu LP, et al. Nat Genet. 2017 Jun;49(6):866-875. doi: 10.1038/ng.3854. Epub 2017 Apr 24. Nat Genet. 2017. PMID: 28436985 Free PMC article.

7

The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy.

Liu S, Marneth AE, Alexe G, Walker SR, Gandler HI, Ye DQ, Labella K, Mathur R, Toniolo PA, Tillgren M, Gokhale PC, Barbie D, Mullally A, Stegmaier K, Frank DA. Liu S, et al. Blood Adv. 2018 Dec 11;2(23):3428-3442. doi: 10.1182/bloodadvances.2018016733. Blood Adv. 2018. PMID: 30504235 Free PMC article.

8

[Expression of musashi-2 gene in leukemia stem cells from acute myeloid leukemia patients].

Ye AF, Han YX, Zhang SH, Li HY, Chen CQ, Wu JB. Ye AF, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Oct;22(5):1235-8. doi: 10.7534/j.issn.1009-2137.2014.05.009. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014. PMID: 25338564 Chinese.

9

Crystal and solution structures of human oncoprotein Musashi-2 N-terminal RNA recognition motif 1.

Lan L, Xing M, Kashipathy M, Douglas J, Gao P, Battaile K, Hanzlik R, Lovell S, Xu L. Lan L, et al. Proteins. 2020 Apr;88(4):573-583. doi: 10.1002/prot.25836. Epub 2019 Oct 29. Proteins. 2020. PMID: 31603583 Free PMC article.

10

Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program.

Park SM, Gönen M, Vu L, Minuesa G, Tivnan P, Barlowe TS, Taggart J, Lu Y, Deering RP, Hacohen N, Figueroa ME, Paietta E, Fernandez HF, Tallman MS, Melnick A, Levine R, Leslie C, Lengner CJ, Kharas MG. Park SM, et al. J Clin Invest. 2015 Mar 2;125(3):1286-98. doi: 10.1172/JCI78440. Epub 2015 Feb 9. J Clin Invest. 2015. PMID: 25664853 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed